Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting
Current Oncology · 05.07.2026 · 33 (7) · 402
DOI: 10.3390/curroncol33070402 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Current Oncology, online erschienen am 05.07.2026. Verfasst von Linhao Ran und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Banan Hospital of Chongqing Medical University, Chongqing 401320, China. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Hemoptysis, Carcinoma, Squamous Cell, Lung Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Medical Science and Technology Research Program of Chongqing Banan Science and Technology Bureau and Chongqing Banan Health Commission.
Abstract (Originalsprache)
Background
The incremental value of iodine-125 (I-125) seed implantation in advanced refractory lung squamous cell carcinoma (LUSC) with hemoptysis treated with bronchial artery chemoembolization (BACE) and immunotherapy remains unclear.
Methods
This retrospective cohort study included 90 patients treated between June 2023 and June 2025. Patients receiving BACE plus immunotherapy were classified according to whether I-125 seed implantation was performed within 7 days after BACE: G1, BACE plus immunotherapy (n = 42), and G2, BACE, I-125 seed implantation, and immunotherapy (n = 48). Inverse probability of treatment weighting (IPTW) served as the primary adjustment method.
Results
After IPTW, baseline covariates were well balanced; propensity score matching yielded 26 patients per group. Compared with G1, G2 was associated with longer hemoptysis-free survival (not reached vs. 11 months; HR = 0.34, 95% CI 0.18–0.64, p < 0.05), overall survival (19 vs. 14 months; HR = 0.26, 95% CI 0.15–0.44, p < 0.05), and progression-free survival (12 vs. 9 months; HR = 0.34, 95% CI 0.21–0.56, p < 0.05). The 6-month objective response rate (ORR) and disease control rate (DCR) were higher in G2, whereas no significant difference in 24-h hemostasis or recorded grade 3 or higher adverse events was observed.
Conclusions
Adding I-125 seed implantation to BACE plus immunotherapy was associated with improved outcomes in selected patients, and prospective validation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Banan Hospital of Chongqing Medical University, Chongqing 401320, China.
- Department of Ultrasound, Banan Hospital of Chongqing Medical University, Chongqing 401320, China.
ORCID-Profile: Linhao Ran
Förderung
- The Medical Science and Technology Research Program of Chongqing Banan Science and Technology Bureau and Chongqing Banan Health Commission
Zitieren
APA
Ran, L., Chen, J., Liang, H., Xie, J., Fu, W., Yang, D., Li, F., Liu, Y., & Jiang, L. (2026). Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting. Current Oncology, 33(7), 402. https://doi.org/10.3390/curroncol33070402
Vancouver
Ran L, Chen J, Liang H, Xie J, Fu W, Yang D, et al. Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting. Current Oncology. 2026;33(7):402. doi:10.3390/curroncol33070402
BibTeX
@article{Ran2026,
author = {Ran, Linhao and Chen, Jiangwei and Liang, Huan and Xie, Jiajian and Fu, Weichen and Yang, Dichun and Li, Fan and Liu, Ying and Jiang, Li},
title = {Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {7},
pages = {402},
doi = {10.3390/curroncol33070402}
}
EUVIMED